Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STRO-001 · 1 trial · 8 indications
Incidence of adverse events (AEs) observed across STRO-001 dose levels
Frequency of dose-limiting toxicity and exposure across STRO-001 dose levels
Objective response rates per International Myeloma Working Group (IMWG) criteria for response assessment
Objective response rates per the Lugano classification for response assessment
| Arm | Type | Description |
|---|---|---|
| STRO-001 | EXPERIMENTAL | intravenous |
| Name | Type | Description |
|---|---|---|
| STRO-001 | DRUG | intravenous antibody drug conjugate |
Key Inclusion Criteria: 1. Confirmation of diagnosis 2. Relapsed or relapsed/refractory disease 3. Age ≥ 18 years 4. ECOG performance status (0-2) 5. Life expectancy \> 3 months 6. Adequate bone marrow and renal functions 7. QTcF \<500 msec 8. Ability to comply with treatment, PK and test schedules...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib |
STRO-001 is an investigational anti-CD74 antibody drug conjugate developed by Sutro Biopharma, Inc. for advanced B-cell malignancies, including B-cell lymphoma. It delivers a cytotoxic payload to cells expressing CD74. It is in Phase 1 clinical development and has not been approved by the FDA.
STRO-001 is being studied for the treatment of advanced B-cell malignancies, including B-cell lymphoma, non-Hodgkin lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, indolent lymphoma, and multiple myeloma. It is investigational and has not been approved for any indication.
STRO-001 targets CD74, a protein expressed on B cells and certain hematologic malignancies. As an antibody drug conjugate, STRO-001 binds CD74 and delivers a cytotoxic payload directly to CD74-expressing tumor cells. This targeted approach aims to concentrate anti-tumor activity on malignant B cells.
STRO-001 is being developed by Sutro Biopharma, Inc., which trades on the Nasdaq under the ticker STRO. The company is the sponsor of the clinical program evaluating STRO-001 in advanced B-cell malignancies.
STRO-001 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 trial evaluating STRO-001 has been completed.
STRO-001 was evaluated in one Phase 1 clinical trial, NCT03424603, titled Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies. The trial enrolled 70 patients in the United States and has been completed. It was an uncontrolled, open-label study.